<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>NMPA</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Innocare Pharma’s ICP-B208 gains IND clearance in China</title>
      <description>
        <![CDATA[Beijing Innocare Pharma Tech Co. Ltd. has received IND approval from China’s National Medical Products Administration (NMPA) for ICP-B208, an antibody-drug conjugate targeting CDH17, which is highly expressed in gastrointestinal cancers, including colorectal, gastric and biliary tract cancers and pancreatic ductal adenocarcinoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730932</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730932-innocare-pharmas-icp-b208-gains-ind-clearance-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/3D-illustration-of-human-digestive-system.webp?t=1709246262" type="image/jpeg" medium="image" fileSize="171684">
        <media:title type="plain">3D illustration of human digestive system</media:title>
      </media:content>
    </item>
    <item>
      <title>China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M</title>
      <description>
        <![CDATA[Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730868</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730868-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/HK-Star-Sports-IPO-5-6.webp?t=1778095416" type="image/jpeg" medium="image" fileSize="144071">
        <media:title type="plain">​Star Sports Medicine HKEX IPO ceremony</media:title>
        <media:description type="plain">Star Sports Medicine's IPO ceremony on May 5.
Credit: HKEX; x.com – @HKEXGroup</media:description>
      </media:content>
    </item>
    <item>
      <title>Simcere Zaiming’s SIM-0613 cleared to enter clinic in China</title>
      <description>
        <![CDATA[Simcere Zaiming Pharmaceutical Co. Ltd.’s SIM-0613 for injection has received clinical trial approval from China’s National Medical Products Administration (NMPA), enabling initiation of a clinical trial for advanced solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730909</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730909-simcere-zaimings-sim-0613-cleared-to-enter-clinic-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-antibody-attack.webp?t=1588880107" type="image/png" medium="image" fileSize="559822">
        <media:title type="plain">Antibodies attacking cancer cell </media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730926</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730926-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730835</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730835-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730579</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730579-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Biogen amasses full felzartamab rights with $850M TJ deal </title>
      <description>
        <![CDATA[Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year license saga. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730485</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730485-biogen-amasses-full-felzartamab-rights-with-850m-tj-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-handshake-silhouette.webp?t=1670353285" type="image/png" medium="image" fileSize="178881">
        <media:title type="plain">Global handshake silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730470</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730470-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>CSPC’s SYS-6051 cleared for clinic in China for solid tumors</title>
      <description>
        <![CDATA[CSPC Pharmaceutical Group Ltd.’s SYS-6051 has gained clinical trial clearance from China’s National Medical Products Administration (NMPA) for advanced solid tumors. SYS-6051 is a human tissue factor-targeted antibody-drug conjugate that binds to tissue factor expressed on the surface of tumor cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730429</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730429-cspcs-sys-6051-cleared-for-clinic-in-china-for-solid-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibody-drug-conjugates-ADCs-3D.webp?t=1751620465" type="image/jpeg" medium="image" fileSize="160333">
        <media:title type="plain">3D rendering of an antibody-drug conjugate</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA accepts Mabwell’s IND application for 6MW5311</title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd.’s has announced IND acceptance by China’s National Medical Products Administration (NMPA) for the company’s LILRB4/CD3 T-cell engager bispecific antibody 6MW5311. The drug candidate is being developed for hematologic malignancies, specifically acute myeloid leukemia (AML), chronic myelomonocytic leukemia and multiple myeloma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730428</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730428-chinas-nmpa-accepts-mabwells-ind-application-for-6mw5311</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/AML-cells-acute-myeloid-leukemia.webp?t=1663340307" type="image/png" medium="image" fileSize="1258935">
        <media:title type="plain">Microscopic image of acute myeloid leukemia (AML) cells.</media:title>
        <media:description type="plain">Acute myeloid leukemia cells. Credit: Cincinnati Children's
</media:description>
      </media:content>
    </item>
    <item>
      <title>Mabwell announces Chinese clinical trial clearance for SST-001</title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd. has announced that SST-001 (18F-FD4), an α-synuclein-targeted PET tracer developed by Mabwell’s incubated company Synusight Biotech, has received clinical trial clearance from China’s National Medical Products Administration (NMPA). The planned phase I trial will enroll healthy volunteers, patients with multiple system atrophy (MSA), and patients with Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730374</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730374-mabwell-announces-chinese-clinical-trial-clearance-for-sst-001</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Radiopharmaceutical-illustration.webp?t=1680558525" type="image/png" medium="image" fileSize="129994">
        <media:title type="plain">Radiopharmaceutical illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Fosun gains clinical trial approval in China for FXB-0871</title>
      <description>
        <![CDATA[Fosun Pharmaceutical (Group) Co. Ltd. has received the approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of FXB-0871 (TEV-56278) for the treatment of locally advanced or metastatic solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730093</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730093-fosun-gains-clinical-trial-approval-in-china-for-fxb-0871</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-blood-vessels.webp?t=1691420296" type="image/jpeg" medium="image" fileSize="242637">
        <media:title type="plain">3D illustration of tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730089</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730089-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Simcere’s rademikibart meets phase III endpoints in atopic dermatitis </title>
      <description>
        <![CDATA[Simcere Pharmaceutical Group Ltd.’s monoclonal antibody, rademikibart (CBP-201), met the primary endpoint in a Chinese phase III study in adults and adolescents with moderate to severe atopic dermatitis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729969</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729969-simceres-rademikibart-meets-phase-iii-endpoints-in-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/monoclonal-antibody-mab.webp?t=1713364043" type="image/jpeg" medium="image" fileSize="243312">
        <media:title type="plain">Monoclonal antibody illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729841</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729841-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Kintor’s KX-826 meets phase III endpoints in alopecia  </title>
      <description>
        <![CDATA[Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the primary endpoint in a pivotal phase III trial in male androgenetic alopecia, and the company will soon file an NDA with China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729893</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729893-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Alopecia.webp?t=1773953185" type="image/jpeg" medium="image" fileSize="1021257">
        <media:title type="plain">Alopecia - hair loss </media:title>
      </media:content>
    </item>
    <item>
      <title>Kelun-Biotech’s SKB-103 cleared to enter clinic in China</title>
      <description>
        <![CDATA[Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has announced IND approval by China’s National Medical Products Administration (NMPA) for SKB-103 for the treatment of advanced solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729855</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729855-kelun-biotechs-skb-103-cleared-to-enter-clinic-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibody-Drug-Conjugate-Molecules-ADC.webp?t=1671207526" type="image/png" medium="image" fileSize="887488">
        <media:title type="plain">3D illustration demonstrating antibody-drug conjugate.</media:title>
      </media:content>
    </item>
    <item>
      <title>Kintor’s KX-826 meets phase III endpoints in alopecia  </title>
      <description>
        <![CDATA[Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the primary endpoint in a pivotal phase III trial in male androgenetic alopecia, and the company will soon file an NDA with China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729749</guid>
      <pubDate>Thu, 19 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729749-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Alopecia.webp?t=1773953185" type="image/jpeg" medium="image" fileSize="1021257">
        <media:title type="plain">Alopecia - hair loss </media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Qyuns moves IL-17 biologic toward first approval</title>
      <description>
        <![CDATA[Qyuns Therapeutics Co. Ltd. has moved closer to its first commercial product after China’s National Medical Products Administration (NMPA) accepted its NDA for IL-17 antibody crusekitug (QX-002N) for treating ankylosing spondylitis (AS), a chronic inflammatory disease that affects the spine and sacroiliac joints.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729710</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729710-chinas-qyuns-moves-il-17-biologic-toward-first-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Inflamed-Lumbar-Spine-Disc.webp?t=1773260221" type="image/jpeg" medium="image" fileSize="666699">
        <media:title type="plain">Illustration of inflamed spine</media:title>
      </media:content>
    </item>
    <item>
      <title>Hightide wins China NDA acceptance for oral metabolic therapy</title>
      <description>
        <![CDATA[China’s National Medical Products Administration (NMPA) has accepted for review Hightide Therapeutics Inc.’s NDA for HTD-1801 for type 2 diabetes, marking the Shenzhen-based company’s first NDA submission and a major step toward commercialization.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729709</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729709-hightide-wins-china-nda-acceptance-for-oral-metabolic-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Diabetes/diabetes-management.webp?t=1593552366" type="image/png" medium="image" fileSize="190736">
        <media:title type="plain">doctor, checklist, apple, prescription bottle and blood glucose meter illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>CF Pharmtech’s ICF-001 cleared for clinic in China</title>
      <description>
        <![CDATA[CF Pharmtech Inc. has announced IND approval by China’s National Medical Products Administration (NMPA) for ICF-001, a long-acting inhalation powder candidate for the treatment of pulmonary hypertension and related severe pulmonary diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729648</guid>
      <pubDate>Mon, 16 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729648-cf-pharmtechs-icf-001-cleared-for-clinic-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Respiratory-Disorders.webp?t=1589292629" type="image/png" medium="image" fileSize="574575">
        <media:title type="plain">Internal organs: lungs, heart, stomach, diaphragm</media:title>
      </media:content>
    </item>
    <item>
      <title>China NMPA clears IND for Akeso’s trispecific antibody</title>
      <description>
        <![CDATA[Akeso Inc.’s first-in-class trispecific antibody, AK-150, has received IND clearance from China’s National Medical Products Administration (NMPA) for clinical trials in patients with advanced solid tumors. Engineered using Akeso’s AI-driven drug discovery platform and its proprietary Tetrabody technology, AK-150 is a humanized anti-CSF-1R, ILT2 and ILT4 trispecific antibody that achieves multipathway blockade of both innate and adaptive immunity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729646</guid>
      <pubDate>Mon, 16 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729646-china-nmpa-clears-ind-for-akesos-trispecific-antibody</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/cancer-tumor-crosshairs-target.webp?t=1711120097" type="image/jpeg" medium="image" fileSize="283816">
        <media:title type="plain">Concept art for targeting cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Qyuns moves IL-17 biologic toward first approval</title>
      <description>
        <![CDATA[Qyuns Therapeutics Co. Ltd. has moved closer to its first commercial product after China’s National Medical Products Administration (NMPA) accepted its NDA for IL-17 antibody crusekitug (QX-002N) for treating ankylosing spondylitis (AS), a chronic inflammatory disease that affects the spine and sacroiliac joints.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729467</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729467-chinas-qyuns-moves-il-17-biologic-toward-first-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Inflamed-Lumbar-Spine-Disc.webp?t=1773260221" type="image/jpeg" medium="image" fileSize="666699">
        <media:title type="plain">Illustration of inflamed spine</media:title>
      </media:content>
    </item>
    <item>
      <title>Hightide wins China NDA acceptance for oral metabolic therapy</title>
      <description>
        <![CDATA[China’s National Medical Products Administration (NMPA) has accepted for review Hightide Therapeutics Inc.’s NDA for HTD-1801 for type 2 diabetes, marking the Shenzhen-based company’s first NDA submission and a major step toward commercialization.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729464</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729464-hightide-wins-china-nda-acceptance-for-oral-metabolic-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Diabetes/diabetes-management.webp?t=1593552366" type="image/png" medium="image" fileSize="190736">
        <media:title type="plain">doctor, checklist, apple, prescription bottle and blood glucose meter illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>China approves first noninvasive therapy for cervical precancer</title>
      <description>
        <![CDATA[China’s National Medical Products Administration has approved Asieris Pharmaceuticals Co. Ltd.’s cold light photodynamic drug-device combination product, Cevira (APL-1702, hexaminolevulinate hydrochloride), which is used as a nonsurgical therapy for treating patients with cervical intraepithelial neoplasia grade 2.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729585</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729585-china-approves-first-noninvasive-therapy-for-cervical-precancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/women-gyno-uterus-ovary.webp?t=1589293258" type="image/png" medium="image" fileSize="483965">
        <media:title type="plain">Fallopian tubes, ovaries and uterus</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA clears HBM-7575 to enter clinic in atopic dermatitis</title>
      <description>
        <![CDATA[Harbour Biomed Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. have announced IND approval by China’s National Medical Products Administration (NMPA) for HBM-7575 (SKB-575) for the treatment of atopic dermatitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729413</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729413-chinas-nmpa-clears-hbm-7575-to-enter-clinic-in-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Green-and-red-bispecific-antibodies.webp?t=1741632039" type="image/jpeg" medium="image" fileSize="108053">
        <media:title type="plain">Green and red bispecific antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA clears China Medical System’s CMS-D008 for clinic</title>
      <description>
        <![CDATA[China Medical System Holdings Ltd. has received clinical trial approval from China’s National Medical Products Administration (NMPA) for CMS-D008 injection for overweight or obese individuals.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729394</guid>
      <pubDate>Fri, 06 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729394-chinas-nmpa-clears-china-medical-systems-cms-d008-for-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-3D-illustration.webp?t=1725482193" type="image/jpeg" medium="image" fileSize="212050">
        <media:title type="plain">3D illustration of RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>China approves first noninvasive therapy for cervical precancer</title>
      <description>
        <![CDATA[China’s National Medical Products Administration has approved Asieris Pharmaceuticals Co. Ltd.’s cold light photodynamic drug-device combination product, Cevira (APL-1702, hexaminolevulinate hydrochloride), which is used as a nonsurgical therapy for treating patients with cervical intraepithelial neoplasia grade 2.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729303</guid>
      <pubDate>Wed, 04 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729303-china-approves-first-noninvasive-therapy-for-cervical-precancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/women-gyno-uterus-ovary.webp?t=1589293258" type="image/png" medium="image" fileSize="483965">
        <media:title type="plain">Fallopian tubes, ovaries and uterus</media:title>
      </media:content>
    </item>
    <item>
      <title>UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE</title>
      <description>
        <![CDATA[Belgian pharma giant UCB SA is putting skin in the bispecific T-cell engager (TCE) game, announcing a potential $1.1 billion deal to license Antengene Corp.’s ATG-201. ATG-201 is a CD19/CD3 bispecific TCE antibody aimed at autoimmune disorders, though specific indications were not disclosed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729298</guid>
      <pubDate>Wed, 04 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729298-ucb-inks-11b-deal-for-antengenes-autoimmune-bispecific-tce</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Red-and-blue-bispecific-antibodies.webp?t=1765991281" type="image/jpeg" medium="image" fileSize="372546">
        <media:title type="plain">Red and blue bispecific antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Systimmune’s iza-bren hits phase III breast cancer goals in China</title>
      <description>
        <![CDATA[In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729321</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729321-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-wireframe.webp?t=1706887459" type="image/jpeg" medium="image" fileSize="349651">
        <media:title type="plain">Cancer tumor in breast illustration</media:title>
      </media:content>
    </item>
  </channel>
</rss>
